| Metabolite profiling and identification of enzymes responsible for the metabolism of mitragynine, the major alkaloid of Mitragyna speciosa (kratom) |
15 |
| Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans |
10 |
| Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys |
10 |
| Effects of verapamil on the pharmacokinetics of dihydromyricetin in rats and its potential mechanism |
9 |
| Effects of astragaloside IV on the pharmacokinetics of puerarin in rats |
8 |
| Influence of grapefruit juice on pharmacokinetics of triptolide in rats grapefruit juice on the effects of triptolide |
8 |
| Prediction of human pharmacokinetics of long half-life compounds using chimeric mice with humanised liver |
7 |
| Identification and analysis of the reactive metabolites related to the hepatotoxicity of safrole |
7 |
| Metabolism of deltamethrin and cis- and trans-permethrin by human expressed cytochrome P450 and carboxylesterase enzymes |
7 |
| Glucuronidation of icaritin by human liver microsomes, human intestine microsomes and expressed UDP-glucuronosyltransferase enzymes: identification of UGT1A 1A9 and 2B7 as the main contributing enzymes |
7 |
| Metabolism of deltamethrin and cis- and trans-permethrin by rat and human liver microsomes, liver cytosol and plasma preparations |
7 |
| Prediction of human pharmacokinetics of typical compounds by a physiologically based method using chimeric mice with humanized liver |
7 |
| In vitro inhibitory effects of pristimerin on human liver cytochrome P450 enzymes |
7 |
| Metabolic profile elucidation of Zhi-Zi-Da-Huang decoction in rat intestinal bacteria using high-resolution mass spectrometry combined with multiple analytical perspectives |
6 |
| Pharmacokinetics and brain penetration study of chlorogenic acid in rats |
6 |
| Interactions of organophosphorus pesticides with solute carrier (SLC) drug transporters |
6 |
| A metabolomic perspective of pazopanib-induced acute hepatotoxicity in mice |
6 |
| Comparison of uptake transporter functions in hepatocytes in different species to determine the optimal model for evaluating drug transporter activities in humans |
6 |
| Antiretroviral concentrations and surrogate measures of efficacy in the brain tissue and CSF of preclinical species |
6 |
| Phase I and phase II metabolism simulation of antitumor-active 2-hydroxyacridinone with electrochemistry coupled on-line with mass spectrometry |
5 |
| Uptake and metabolism of carbamazepine (CBZ) by clam Ruditapes decussatus and its effects in biochemical responses |
5 |
| The effect of fenofibric acid on the pharmacokinetics and pharmacodynamics of warfarin in rats |
5 |
| Reappraisal and perspectives of clinical drug-drug interaction potential of alpha-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus |
5 |
| Metabolic map of osthole and its effect on lipids |
5 |
| Efflux proteins at the blood-brain barrier: review and bioinformatics analysis |
4 |
| Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition |
4 |
| Non-clinical pharmacokinetic profiles of rovatirelin, an orally available thyrotropin-releasing hormone analogue |
4 |
| In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin |
4 |
| Dose proportionality and pharmacokinetics of dronedarone following intravenous and oral administration to rat |
4 |
| Development of new Coumarin-based profluorescent substrates for human cytochrome P450 enzymes |
4 |
| Preclinical pharmacokinetics of a novel anti-c-Met antibody-drug conjugate, SHR-A in rodents and non-human primates |
4 |
| Absorption, metabolism and excretion of [C-14]omarigliptin, a once-weekly DPP-4 inhibitor, in humans |
4 |
| Aromatase inhibition by 2-methyl indole hydrazone derivatives evaluated via molecular docking and in vitro activity studies |
4 |
| Effects of quercetin on the pharmacokinetics of losartan and its metabolite EXP3174 in rats |
4 |
| Effect Of epigallocatechin-3-gallate on the pharmacokinetics of amlodipine in rats |
4 |
| Characterization of in vitro and in vivo metabolism of leelamine using liquid chromatography-tandem mass spectrometry |
4 |
| Effects of verapamil on the pharmacokinetics of puerarin in rats |
4 |
| Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin |
4 |
| The influence of physicochemical properties on the reactivity and stability of acyl glucuronides |
4 |
| Oxidation of 1-chloropyrene by human CYP1 family and CYP2A subfamily cytochrome P450 enzymes: catalytic roles of two CYP1B1 and five CYP2A13 allelic variants |
3 |
| Altered hepatic drug-metabolizing activity in rats suffering from hypoxemia with experimentally induced acute lung impairment |
3 |
| Bisphenol S modulates concentrations of bisphenol A and oestradiol in female and male mice |
3 |
| The impact of azole antifungal drugs on imatinib metabolism in human liver microsomes |
3 |
| Functionally relevant genetic variants of glutathione S-transferase GSTM5 in cynomolgus and rhesus macaques |
3 |
| In vitro inhibitory effects of sophocarpine on human liver cytochrome P450 enzymes |
3 |
| Metabonomics analysis of serum from rats given long-term and low-level cadmium by ultra-performance liquid chromatography-mass spectrometry |
3 |
| Disposition of [C-14]hydroquinone in Harlan Sprague-Dawley rats and B6C3F1/N mice: species and route comparison |
3 |
| Application of unbound liver-to-plasma concentration ratio to quantitative projection of cytochrome P450-mediated drug-drug interactions using physiologically based pharmacokinetic modelling approach |
3 |
| Evaluation of the inhibition of human carboxylesterases (CESs) by the active ingredients from Schisandra chinensis |
3 |
| Gut microbiota metabolizes nabumetone in vitro: Consequences for its bioavailability in vivo in the rodents with altered gut microbiome |
3 |
